文献速递眼底病与葡萄膜炎眼整形与眼眶

阿达木单抗诱导白塞病葡萄膜炎临床缓解后NK细胞表型、受体与功能的变化

Adalimumab-Induced Changes in NK Cells Phenotype, Receptors, and Functions After Clinical Remission of Behçet's Uveitis.
PubMed 文献 · Am J Ophthalmol · 2026-01-19

该前瞻性队列研究纳入活动期白塞病葡萄膜炎(BU)14例、强直性脊柱炎(AS)13例及健康对照23例,在基线及阿达木单抗治疗后3个月检测外周NK细胞表型、受体、细胞毒分子及细胞因子。阿达木单抗改善BU活动度及AS病情,并上调NK细胞NKG2A表达;BU中NK表型向CD56dimCD16⁻(耗竭样)偏移、CD56⁻CD16bright细胞减少,且IL-10/IL-17特征升高,而AS以TNF-α/IFN-γ为主。

要点

  • BU与AS活动期均表现为NKG2D升高、NKG2A降低,阿达木单抗可上调NKG2A。
  • BU缓解后NK细胞向CD56dimCD16⁻耗竭样表型偏移,CD56⁻CD16bright细胞减少。
  • BU以IL-10/IL-17特征为主,AS以TNF-α/IFN-γ为主,缓解后BU细胞毒活性仍可诱导。

核心结论

  • BU与AS共享相似的NK细胞活化通路。
  • 阿达木单抗在BU中重新平衡NK活化/抑制性受体(NKG2A升高、NKG2D持续),收缩细胞毒效应细胞并向耗竭样表型偏移,与临床改善平行。
  • NK受体平衡可作为药效学生物标志物候选。

研究设计与样本

  • 前瞻性临床队列,重复测量(基线及第3个月)。
  • BU活动期14例、AS疾病对照13例、健康对照23例。
  • BU活动度采用裂隙灯/眼底检查、BCVA、OCT及FFA渗漏评分评估;AS活动度采用BASDAI评估。
  • 流式细胞术检测外周NK细胞六种CD56/CD16亚群、检查点受体(NKG2A、NKG2D、NKp46)、脱颗粒/细胞毒分子(CD107a、颗粒酶A、穿孔素)及细胞内细胞因子(IFN-γ、TNF-α、IL-17、IL-4、IL-10、TGF-β)。
  • 血浆细胞因子/可溶性细胞毒介质采用多珠基检测定量。

主要发现

  • 阿达木单抗改善BU活动度(FFA渗漏、BCVA、CMT)及AS的BASDAI。
  • 活动期BU与AS的NKG2D表达高于对照、NKG2A表达低于对照;阿达木单抗增加NK细胞NKG2A表达。
  • BU中阿达木单抗使NK表型向CD56dimCD16⁻(耗竭样)偏移并减少CD56⁻CD16bright细胞。
  • BU的NK细胞IL-10/IL-17特征升高,AS以TNF-α/IFN-γ为主。
  • BU缓解后细胞毒活性(CD107a、颗粒酶A)仍可诱导。

临床怎么用

  • 监测NK细胞NKG2A/NKG2D平衡可能有助于评估阿达木单抗在BU中的药效学反应。
  • BU与AS的NK活化通路相似,提示NK受体靶向策略值得进一步研究。

局限性

  • 样本量较小(BU 14例、AS 13例、HC 23例)。
  • 仅观察基线及第3个月两个时间点。
  • 未报告NK受体平衡与临床指标间的相关性分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To elucidate adalimumab's mechanism of action in two class-I MHC-associated diseases by characterizing NK cell phenotype and function in Behçet's uveitis (BU) and axial ankylosing spondylitis (AS). DESIGN: Prospective clinical cohort with repeated measures (baseline and month 3). SUBJECTS, PARTICIPANTS, AND/OR CONTROLS: BU (n = 14, active), AS (n = 13, disease control), and healthy controls (HC; n = 23). METHODS, INTERVENTION, OR TESTING: BU activity was assessed by slit-lamp/fundus exam, best-corrected visual acuity (BCVA), OCT, and fluorescein angiography (FFA) leakage score; AS activity by Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). Peripheral NK cells were profiled by flow cytometry for six CD56/CD16 subsets, checkpoint receptors (NKG2A, NKG2D, NKp46), degranulation/cytotoxic molecules (CD107a, granzyme A, perforin), and intracellular cytokines (IFN-γ, TNF-α, IL-17, IL-4, IL-10, TGF-β). Plasma cytokines/soluble cytotoxic mediators were quantified by multiplex bead-based assays. Sampling occurred during active disease and after adalimumab-induced clinical remission (month 3). MAIN OUTCOME MEASURES: Frequencies of six NK-cell subsets (CD56/CD16), surface NKG2A/NKG2D/NKp46 expression, NK degranulation/cytotoxicity (CD107a, granzyme A, perforin; ±K562 stimulation), intracellular NK cytokines (IFN-γ, TNF-α, IL-17, IL-4, IL-10, TGF-β), and plasma cytokines/soluble mediators RESULTS: Adalimumab improved BU activity (FFA leakage, BCVA, CMT) and BASDAI in AS. During activity, BU and AS showed higher NKG2D and lower NKG2A expression than controls; adalimumab increased NKG2A expression on NK cells. In BU, adalimumab shifted NK phenotype toward CD56dimCD16⁻ (exhausted-like) and reduced CD56⁻CD16bright cells. BU NK cells exhibited elevated IL-10/IL-17 signatures, while AS favored TNF-α/IFN-γ. Cytotoxic activity (CD107a, granzyme A) remained inducible in BU after remission. CONCLUSIONS: BU and AS share similar NK activation pathways. In BU, adalimumab rebalances NK activating/inhibitory receptors (increased NKG2A with persistent NKG2D), contracts cytotoxic effector cells, and shifts toward an exhausted-like phenotype in parallel with clinical improvement, supporting NK-receptor balance as a pharmacodynamic biomarker candidate.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Esen F, Kokoglu A, Cetin C, et al. Adalimumab-Induced Changes in NK Cells Phenotype, Receptors, and Functions After Clinical Remission of Behçet's Uveitis. Am J Ophthalmol. 2026. PMID: 41564966. doi:10.1016/j.ajo.2026.01.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。